Karianne Fjeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karianne Fjeld has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
- Anders Molven
Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway
20 shared publications - Bente Berg Johansson
Mohn Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway
13 shared publications Anders Molven
Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen
11 shared publicationsBente B. Johansson
Mohn Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen
10 shared publicationsKhadija El Jellas
10 shared publications- Stefan Johansson
Mohn Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway
10 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1924024
High-fat diet accelerates pancreas pathology in the Cel-HYB1 mouse model
Introduction: The CEL gene encodes the pancreatic enzyme carboxyl ester lipase. The human CEL-HYB1 allele, a hybrid variant of CEL and its adjacent pseudogene CELP , is associated with a five-fold increased risk for chronic pancreatitis in European cohorts. Humanized Cel-HYB1 mice develop chronic pancreatitis spontaneously albeit with a relatively mild presentation. The aim of this study was to further characterize the pancreatic phenotype in Cel-HYB1 mice. Methods: We investigated Cel-HYB1 animals by two complementary approaches. First, we analyzed compound heterozygous Cel-16R/HYB1 mice where the second Cel allele carries the 16-repeat ( 16R ) VNTR of the normal human CEL gene. Second, heterozygous and homozygous Cel-HYB1 animals were fed either a high-fat diet or standard chow for 3 months. All animals were characterized with respect to growth, organ weights, pancreas pathology and glucose metabolism. Results: In the Cel-16R/HYB1 model, body weight, pancreas weight and pancreatic histology were comparable to those of heterozygous Cel-HYB1 mice. However, within each genotype female mice generally exhibited more pronounced pancreatic histopathological changes than males. Male Cel-16R/HYB1 mice had larger fat depots at 6 months of age, and Cel-16R/HYB1 animals of both sexes showed slightly improved glucose tolerance relative to heterozygous Cel-HYB1 mice. When fed a high-fat diet, increased body weights were seen across all mouse groups without genotype-dependent differences. Under this condition, Cel-HYB1 animals displayed more pronounced pancreatic histopathology than littermate controls. Notably, no consistent genotype-dependent differences in glucose tolerance were observed in Cel-HYB1 mice under either high-fat diet or standard chow conditions. Conclusion: The humanized Cel-16R allele did not substantially modify the pancreatic phenotype of Cel-HYB1 mice, although Cel-16R/HYB1 animals exhibited somewhat improved glucose tolerance compared with heterozygous Cel-HYB1 mice. In contrast, high-fat diet promoted exocrine pancreatic pathology, supporting a role for dietary factors as potential modifiers of disease severity in CEL-HYB1 -associated chronic pancreatitis.
- 25 September 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1924024
Open AccessHigh-fat diet accelerates pancreas pathology in the Cel-HYB1 mouse model
Introduction: The CEL gene encodes the pancreatic enzyme carboxyl ester lipase. The human CEL-HYB1 allele, a hybrid variant of CEL and its adjacent pseudogene CELP , is associated with a five-fold increased risk for chronic pancreatitis in European cohorts. Humanized Cel-HYB1 mice develop chronic pancreatitis spontaneously albeit with a relatively mild presentation. The aim of this study was to further characterize the pancreatic phenotype in Cel-HYB1 mice. Methods: We investigated Cel-HYB1 animals by two complementary approaches. First, we analyzed compound heterozygous Cel-16R/HYB1 mice where the second Cel allele carries the 16-repeat ( 16R ) VNTR of the normal human CEL gene. Second, heterozygous and homozygous Cel-HYB1 animals were fed either a high-fat diet or standard chow for 3 months. All animals were characterized with respect to growth, organ weights, pancreas pathology and glucose metabolism. Results: In the Cel-16R/HYB1 model, body weight, pancreas weight and pancreatic histology were comparable to those of heterozygous Cel-HYB1 mice. However, within each genotype female mice generally exhibited more pronounced pancreatic histopathological changes than males. Male Cel-16R/HYB1 mice had larger fat depots at 6 months of age, and Cel-16R/HYB1 animals of both sexes showed slightly improved glucose tolerance relative to heterozygous Cel-HYB1 mice. When fed a high-fat diet, increased body weights were seen across all mouse groups without genotype-dependent differences. Under this condition, Cel-HYB1 animals displayed more pronounced pancreatic histopathology than littermate controls. Notably, no consistent genotype-dependent differences in glucose tolerance were observed in Cel-HYB1 mice under either high-fat diet or standard chow conditions. Conclusion: The humanized Cel-16R allele did not substantially modify the pancreatic phenotype of Cel-HYB1 mice, although Cel-16R/HYB1 animals exhibited somewhat improved glucose tolerance compared with heterozygous Cel-HYB1 mice. In contrast, high-fat diet promoted exocrine pancreatic pathology, supporting a role for dietary factors as potential modifiers of disease severity in CEL-HYB1 -associated chronic pancreatitis.
- Open Access
ERα-regulated IRX3 controls the growth of ER-positive breast tumors
Estrogen receptor positive (ER+) breast cancer is primarily treated with endocrine therapies targeting ERα signaling. Although endocrine therapy has substantially improved survival in ER+ breast cancer, metastatic disease remains largely incurable, underscoring the need to elucidate additional mechanisms driving growth and proliferation. Here, we show that the homeobox protein IRX3 is selectively overexpressed in ER+ breast cancer and define the molecular function of IRX3 in ER+ breast cancer using an integrated combination of in vitro , in vivo and in silico approaches. We uncover a previously uncharacterized distal regulatory region that controls IRX3 transcription via ERα and associated steroid receptor coactivators. Consistent with this regulatory axis, anti-estrogen treatment resulted in marked downregulation of cellular IRX3 levels. Functionally, depletion of IRX3 suppresses proliferation of the human ER+ breast cancer cells in vitro, but paradoxically promotes tumor growth and metastatic dissemination in orthotopic xenografts in vivo by stimulating enhanced tumor vascularization. Finally, low tumor expression of IRX3 correlates with poorer survival outcomes in patients with ER+ breast cancer. Collectively, these findings establish IRX3 as an important regulator of ER+ breast tumor biology and reveal an ERα-dependent role for IRX3 in modulating proliferative and vascular programs in tumor progression. Significance: By identifying a novel ERα-dependent regulatory pathway, this work refines our understanding of how hormone signaling shapes both breast tumor growth and the surrounding microenvironment.
Open AccessERα-regulated IRX3 controls the growth of ER-positive breast tumors
Estrogen receptor positive (ER+) breast cancer is primarily treated with endocrine therapies targeting ERα signaling. Although endocrine therapy has substantially improved survival in ER+ breast cancer, metastatic disease remains largely incurable, underscoring the need to elucidate additional mechanisms driving growth and proliferation. Here, we show that the homeobox protein IRX3 is selectively overexpressed in ER+ breast cancer and define the molecular function of IRX3 in ER+ breast cancer using an integrated combination of in vitro , in vivo and in silico approaches. We uncover a previously uncharacterized distal regulatory region that controls IRX3 transcription via ERα and associated steroid receptor coactivators. Consistent with this regulatory axis, anti-estrogen treatment resulted in marked downregulation of cellular IRX3 levels. Functionally, depletion of IRX3 suppresses proliferation of the human ER+ breast cancer cells in vitro, but paradoxically promotes tumor growth and metastatic dissemination in orthotopic xenografts in vivo by stimulating enhanced tumor vascularization. Finally, low tumor expression of IRX3 correlates with poorer survival outcomes in patients with ER+ breast cancer. Collectively, these findings establish IRX3 as an important regulator of ER+ breast tumor biology and reveal an ERα-dependent role for IRX3 in modulating proliferative and vascular programs in tumor progression. Significance: By identifying a novel ERα-dependent regulatory pathway, this work refines our understanding of how hormone signaling shapes both breast tumor growth and the surrounding microenvironment.
- Open Access
- 14 February 2025
- Published by Elsevier in Gastroenterology
- Vol. 169 (1) , 161-164.e6
The MODY-Causing Mutation of the Human Carboxyl Ester Lipase Gene (CEL) Triggers Chronic Pancreatitis But Not Diabetes in Mice
- 14 February 2025
- Published by Elsevier in Gastroenterology
- Vol. 169 (1) , 161-164.e6
Open AccessThe MODY-Causing Mutation of the Human Carboxyl Ester Lipase Gene (CEL) Triggers Chronic Pancreatitis But Not Diabetes in Mice
- Open Access
- 14 March 2024
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 33 (11) , 1001-1014
Common single-base insertions in the VNTR of the carboxyl ester lipase (CEL) gene are benign and also likely to arise somatically in the exocrine pancreas
The CEL gene encodes carboxyl ester lipase, a pancreatic digestive enzyme. CEL is extremely polymorphic due to a variable number tandem repeat (VNTR) located in the last exon. Single-base deletions within this VNTR cause the inherited disorder MODY8, whereas little is known about VNTR single-base insertions in pancreatic disease. We therefore mapped CEL insertion variants (CEL-INS) in 200 Norwegian patients with pancreatic neoplastic disorders. Twenty-eight samples (14.0%) carried CEL-INS alleles. Most common were insertions in repeat 9 (9.5%), which always associated with a VNTR length of 13 repeats. The combined INS allele frequency (0.078) was similar to that observed in a control material of 416 subjects (0.075). We performed functional testing in HEK293T cells of a set of CEL-INS variants, in which the insertion site varied from the first to the 12th VNTR repeat. Lipase activity showed little difference among the variants. However, CEL-INS variants with insertions occurring in the most proximal repeats led to protein aggregation and endoplasmic reticulum stress, which upregulated the unfolded protein response. Moreover, by using a CEL-INS-specific antibody, we observed patchy signals in pancreatic tissue from humans without any CEL-INS variant in the germline. Similar pancreatic staining was seen in knock-in mice expressing the most common human CEL VNTR with 16 repeats. CEL-INS proteins may therefore be constantly produced from somatic events in the normal pancreatic parenchyma. This observation along with the high population frequency of CEL-INS alleles strongly suggests that these variants are benign, with a possible exception for insertions in VNTR repeats 1–4.
- 14 March 2024
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 33 (11) , 1001-1014
Open AccessCommon single-base insertions in the VNTR of the carboxyl ester lipase (CEL) gene are benign and also likely to arise somatically in the exocrine pancreas
The CEL gene encodes carboxyl ester lipase, a pancreatic digestive enzyme. CEL is extremely polymorphic due to a variable number tandem repeat (VNTR) located in the last exon. Single-base deletions within this VNTR cause the inherited disorder MODY8, whereas little is known about VNTR single-base insertions in pancreatic disease. We therefore mapped CEL insertion variants (CEL-INS) in 200 Norwegian patients with pancreatic neoplastic disorders. Twenty-eight samples (14.0%) carried CEL-INS alleles. Most common were insertions in repeat 9 (9.5%), which always associated with a VNTR length of 13 repeats. The combined INS allele frequency (0.078) was similar to that observed in a control material of 416 subjects (0.075). We performed functional testing in HEK293T cells of a set of CEL-INS variants, in which the insertion site varied from the first to the 12th VNTR repeat. Lipase activity showed little difference among the variants. However, CEL-INS variants with insertions occurring in the most proximal repeats led to protein aggregation and endoplasmic reticulum stress, which upregulated the unfolded protein response. Moreover, by using a CEL-INS-specific antibody, we observed patchy signals in pancreatic tissue from humans without any CEL-INS variant in the germline. Similar pancreatic staining was seen in knock-in mice expressing the most common human CEL VNTR with 16 repeats. CEL-INS proteins may therefore be constantly produced from somatic events in the normal pancreatic parenchyma. This observation along with the high population frequency of CEL-INS alleles strongly suggests that these variants are benign, with a possible exception for insertions in VNTR repeats 1–4.
- 12 October 2023
- Published by Elsevier in Pancreatology
- Vol. 23, e29
The CEL gene in chronic pancreatitis: characterisation of a new humanised compound heterozygous Cel16R/HYB1 mouse model
- 12 October 2023
- Published by Elsevier in Pancreatology
- Vol. 23, e29
The CEL gene in chronic pancreatitis: characterisation of a new humanised compound heterozygous Cel16R/HYB1 mouse model
- Open Access
- 8 November 2022
- Published by Elsevier in Pancreatology
- Vol. 22 (8) , 1099-1111
The genetic risk factor CEL-HYB1 causes proteotoxicity and chronic pancreatitis in mice
- 8 November 2022
- Published by Elsevier in Pancreatology
- Vol. 22 (8) , 1099-1111
Open AccessThe genetic risk factor CEL-HYB1 causes proteotoxicity and chronic pancreatitis in mice
- 16 October 2020
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 33 (6) , 839-843
Protein misfolding in combination with other risk factors in CEL-HYB1-mediated chronic pancreatitis
Objectives: The hybrid allele of the carboxyl ester lipase gene (CEL-HYB1) is a genetic risk factor for chronic pancreatitis (CP) although the mechanism promoting disease development is largely unknown. Here, we aimed to clinically describe subjects carrying the CEL-HYB1 allele and to elucidate why the protein product is pathogenic by analyzing pancreatic secretions and cellular models. Methods: Norwegian cases (n = 154) diagnosed with recurrent acute pancreatitis or CP were subjected to genetic screening by a CEL-HYB1-specific PCR assay followed by Sanger sequencing. For investigation of CEL-HYB1 protein secretion, duodenal juice samples from cases and controls were analyzed by western blotting. HEK293cells were transfected with constructs expressing CEL-HYB1 or the normal CEL protein (CEL-WT) and analyzed by qPCR, cell fractionation and western blotting. Results: Two CEL-HYB1-positive families were identified. In both pedigrees, CEL-HYB1 did not fully co-segregate with disease. One proband had recurrent acute pancreatitis and was an active smoker. Her mother was a CEL-HYB1 carrier who had suffered from several attacks of acute pancreatitis until she stopped smoking. The other proband was diagnosed with CP and pancreas divisum. Her CEL-HYB1-positive parent was symptom-free but exhibited pancreatic imaging changes. When analyzing the CEL protein in duodenal juice, CEL-WT was readily detectable but no band corresponding to the risk variant was seen. In CEL-HYB1-transfected cells, we observed impaired protein secretion, protein aggregation and endoplasmic reticulum stress. Conclusion: Our data suggest that CEL-HYB1, in combination with well-known pancreatitis risk factors, causes disease through the misfolding-dependent pathway of genetic CP risk.
- 16 October 2020
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 33 (6) , 839-843
Protein misfolding in combination with other risk factors in CEL-HYB1-mediated chronic pancreatitis
Objectives: The hybrid allele of the carboxyl ester lipase gene (CEL-HYB1) is a genetic risk factor for chronic pancreatitis (CP) although the mechanism promoting disease development is largely unknown. Here, we aimed to clinically describe subjects carrying the CEL-HYB1 allele and to elucidate why the protein product is pathogenic by analyzing pancreatic secretions and cellular models. Methods: Norwegian cases (n = 154) diagnosed with recurrent acute pancreatitis or CP were subjected to genetic screening by a CEL-HYB1-specific PCR assay followed by Sanger sequencing. For investigation of CEL-HYB1 protein secretion, duodenal juice samples from cases and controls were analyzed by western blotting. HEK293cells were transfected with constructs expressing CEL-HYB1 or the normal CEL protein (CEL-WT) and analyzed by qPCR, cell fractionation and western blotting. Results: Two CEL-HYB1-positive families were identified. In both pedigrees, CEL-HYB1 did not fully co-segregate with disease. One proband had recurrent acute pancreatitis and was an active smoker. Her mother was a CEL-HYB1 carrier who had suffered from several attacks of acute pancreatitis until she stopped smoking. The other proband was diagnosed with CP and pancreas divisum. Her CEL-HYB1-positive parent was symptom-free but exhibited pancreatic imaging changes. When analyzing the CEL protein in duodenal juice, CEL-WT was readily detectable but no band corresponding to the risk variant was seen. In CEL-HYB1-transfected cells, we observed impaired protein secretion, protein aggregation and endoplasmic reticulum stress. Conclusion: Our data suggest that CEL-HYB1, in combination with well-known pancreatitis risk factors, causes disease through the misfolding-dependent pathway of genetic CP risk.
- 9 September 2020
- Published by Wiley in Human Mutation
- Vol. 41 (11) , 1967-1978
Single nucleotide polymorphisms in CEL‐HYB1 increase risk for chronic pancreatitis through proteotoxic misfolding
Genetic variants contribute to the risk of chronic pancreatitis (CP) in adults and children. The risk variant CEL‐HYB1, a recombinant hybrid allele of CEL and its neighboring pseudogene (CELP), encodes a pathogenic variant of the pancreatic digestive enzyme carboxyl ester lipase (CEL). We previously identified combinations of two non‐synonymous SNPs, c.1463T>C (p. Ile488Thr) and c.1643C>T (p. Thr548Ile), in the break point region of CEL‐HYB1. Herein, we tested whether these missense variants alter CP risk and their impact on functional properties of the CEL‐HYB1 protein. Examination of CEL‐HYB1 haplotypes in European patients and controls revealed that the combinationThr488‐Ile548 was present only in cases (p ≤ .001). The lipase activity of purified recombinant CEL‐HYB1 variants showed normal or near normal activity. CEL‐HYB variants expressed in HEK293T cells all had decreased secretion compared with CEL, formed intracellular protein aggregates, and triggered endoplasmic reticulum stress. Thus, we propose that the presence of missense variants in CEL‐HYB increases the pathogenicity of CEL‐HYB1 through misfolding and gain‐of‐function proteotoxicity. Interestingly, Thr488‐Ile548 and Thr488‐Thr548 were equally pathogenic in the functional assays even though only the Thr488‐Ile548 haplotype was significantly enriched in cases. The explanation for the mismatch between genetic and functional data requires further investigation.
- 9 September 2020
- Published by Wiley in Human Mutation
- Vol. 41 (11) , 1967-1978
Single nucleotide polymorphisms in CEL‐HYB1 increase risk for chronic pancreatitis through proteotoxic misfolding
Genetic variants contribute to the risk of chronic pancreatitis (CP) in adults and children. The risk variant CEL‐HYB1, a recombinant hybrid allele of CEL and its neighboring pseudogene (CELP), encodes a pathogenic variant of the pancreatic digestive enzyme carboxyl ester lipase (CEL). We previously identified combinations of two non‐synonymous SNPs, c.1463T>C (p. Ile488Thr) and c.1643C>T (p. Thr548Ile), in the break point region of CEL‐HYB1. Herein, we tested whether these missense variants alter CP risk and their impact on functional properties of the CEL‐HYB1 protein. Examination of CEL‐HYB1 haplotypes in European patients and controls revealed that the combinationThr488‐Ile548 was present only in cases (p ≤ .001). The lipase activity of purified recombinant CEL‐HYB1 variants showed normal or near normal activity. CEL‐HYB variants expressed in HEK293T cells all had decreased secretion compared with CEL, formed intracellular protein aggregates, and triggered endoplasmic reticulum stress. Thus, we propose that the presence of missense variants in CEL‐HYB increases the pathogenicity of CEL‐HYB1 through misfolding and gain‐of‐function proteotoxicity. Interestingly, Thr488‐Ile548 and Thr488‐Thr548 were equally pathogenic in the functional assays even though only the Thr488‐Ile548 haplotype was significantly enriched in cases. The explanation for the mismatch between genetic and functional data requires further investigation.
- Open Access
- 2 September 2020
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 44 (1) , 240-252
Functional evaluation of 16 SCHAD missense variants: Only amino acid substitutions causing congenital hyperinsulinism of infancy lead to loss‐of‐function phenotypes in vitro
Short‐chain 3‐hydroxyacyl‐CoA dehydrogenase (SCHAD), encoded by the HADH gene, is a ubiquitously expressed mitochondrial enzyme involved in fatty acid oxidation. This protein also plays a role in insulin secretion as recessive HADH mutations cause congenital hyperinsulinism of infancy (CHI) via loss of an inhibitory interaction with glutamate dehydrogenase (GDH). Here, we present a functional evaluation of 16 SCHAD missense variants identified either in CHI patients or by high‐throughput sequencing projects in various populations. To avoid interactions with endogenously produced SCHAD protein, we assessed protein stability, subcellular localization, and GDH interaction in a SCHAD knockout HEK293 cell line constructed by CRISPR‐Cas9 methodology. We also established methods for efficient SCHAD expression and purification in E. coli, and tested enzymatic activity of the variants. Our analyses showed that rare variants of unknown significance identified in populations generally had similar properties as normal SCHAD. However, the CHI‐associated variants p.Gly34Arg, p.Ile184Phe, p.Pro258Leu, and p.Gly303Ser were unstable with low protein levels detectable when expressed in HEK293 cells. Moreover, CHI variants p.Lys136Glu, p.His170Arg, and p.Met188Val presented normal protein levels but displayed clearly impaired enzymatic activity in vitro, and their interaction with GDH appeared reduced. Our results suggest that pathogenic missense variants of SCHAD either make the protein target of a post‐translational quality control system or can impair the function of SCHAD without influencing its steady‐state protein level. We did not find any evidence that rare SCHAD missense variants observed only in the general population and not in CHI patients are functionally affected.
- 2 September 2020
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 44 (1) , 240-252
Open AccessFunctional evaluation of 16 SCHAD missense variants: Only amino acid substitutions causing congenital hyperinsulinism of infancy lead to loss‐of‐function phenotypes in vitro
Short‐chain 3‐hydroxyacyl‐CoA dehydrogenase (SCHAD), encoded by the HADH gene, is a ubiquitously expressed mitochondrial enzyme involved in fatty acid oxidation. This protein also plays a role in insulin secretion as recessive HADH mutations cause congenital hyperinsulinism of infancy (CHI) via loss of an inhibitory interaction with glutamate dehydrogenase (GDH). Here, we present a functional evaluation of 16 SCHAD missense variants identified either in CHI patients or by high‐throughput sequencing projects in various populations. To avoid interactions with endogenously produced SCHAD protein, we assessed protein stability, subcellular localization, and GDH interaction in a SCHAD knockout HEK293 cell line constructed by CRISPR‐Cas9 methodology. We also established methods for efficient SCHAD expression and purification in E. coli, and tested enzymatic activity of the variants. Our analyses showed that rare variants of unknown significance identified in populations generally had similar properties as normal SCHAD. However, the CHI‐associated variants p.Gly34Arg, p.Ile184Phe, p.Pro258Leu, and p.Gly303Ser were unstable with low protein levels detectable when expressed in HEK293 cells. Moreover, CHI variants p.Lys136Glu, p.His170Arg, and p.Met188Val presented normal protein levels but displayed clearly impaired enzymatic activity in vitro, and their interaction with GDH appeared reduced. Our results suggest that pathogenic missense variants of SCHAD either make the protein target of a post‐translational quality control system or can impair the function of SCHAD without influencing its steady‐state protein level. We did not find any evidence that rare SCHAD missense variants observed only in the general population and not in CHI patients are functionally affected.
- 1 April 2020
- Published by Elsevier in Pancreatology
- Vol. 20 (3) , 377-384
Characterization of CEL-DUP2: Complete duplication of the carboxyl ester lipase gene is unlikely to influence risk of chronic pancreatitis
- 1 April 2020
- Published by Elsevier in Pancreatology
- Vol. 20 (3) , 377-384
Characterization of CEL-DUP2: Complete duplication of the carboxyl ester lipase gene is unlikely to influence risk of chronic pancreatitis